Tempest Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Tempest Therapeutics, Inc. (TPST) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 135.00% for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-05-14
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 135.00%.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2021-03-31 was 75.00%, a 3.85% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2020-09-30 was 77.00%, a 4.94% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2020-06-30 was 77.00%, a 2.53% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2020 was 77.00%, a 3.75% decline from fiscal 2019.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2019 was 80.00%, a 21.21% increase from fiscal 2018.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2018 was 66.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2026-03-31 | 135.00% 10-Q · filed 2026-05-14 | |||
| 2021-03-31 | 75.00% 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 77.00% 10-K · filed 2021-03-29 | |||
| 2020-09-30 | 77.00% 10-Q · filed 2020-11-09 | 77.00% 10-Q · filed 2020-11-09 | ||
| 2020-06-30 | 77.00% 10-Q · filed 2020-08-10 | 77.00% 10-Q · filed 2020-08-10 | ||
| 2020-03-31 | 78.00% 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | 80.00% 10-K · filed 2021-03-29 | |||
| 2019-09-30 | 81.00% 10-Q · filed 2020-11-09 | 80.00% 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | 79.00% 10-Q · filed 2020-08-10 | 80.00% 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | 80.00% 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | 66.00% 10-K · filed 2020-03-11 | |||
| 2018-09-30 | 65.00% 10-Q · filed 2019-11-13 | 65.00% 10-Q · filed 2019-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |